Published in Mov Disord on May 01, 2004
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain (2011) 1.55
Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials? World J Surg (2006) 1.10
A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol (2010) 1.02
Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J (2009) 0.99
A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol (2013) 0.84
A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability. J Neurol Neurosurg Psychiatry (2011) 0.84
Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease. J Neurol Neurosurg Psychiatry (2014) 0.82
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease. BMC Neurol (2016) 0.75